Wockhardt announced that it has received final approval from the FDA for Alfuzosin HCl Extended-Release Tablets, the generic version of Sanofi-AventisUroxatral.

Alfuzosin HCl is an α1-blocker indicated in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). It works by blocking sympathetic activity and relaxing the smooth muscle component of prostatic hypertrophy, allowing the urine to flow out more easily.

Alfuzosin HCl Extended-Release Tablets will be available in 10mg dosage strength tablets and are being launched immediately.

For more information call (800) 346-6854 or visit www.wockhardt.com.